Category Archives: HIV/AIDS

ShangRing: WHO approval of second nonsurgical circumcision device sets stage for accelerated access to HIV prevention measure

By on .

Latest device approved for use on adolescents, broadening scope of low-cost intervention Call it “VMMC,” for voluntary medical male circumcision, or the current, and more concise “MC” for medical circumcision, by any name, removing men’s foreskins has been proven to lower their risks of acquiring HIV through vaginal sexual intercourse by as much as 60 […]

UNAIDS, Lancet: Take accelerated action on HIV treatment access, research and development, and address epidemic drivers, or risk rebound

By on .

. ” . . . the question is no longer whether the fight against AIDS can be won; the only questions are: will it be won — and when?” An international commission of scientists and others involved in and affected by responses to the global HIV pandemic released findings from a two-year examination of what […]

Diminishing research dollars sparks disease comparisons, competition, while HIV advocates say now is not the time to ease efforts

By on .

As U.S. House and Senate Appropriation Committee members prepare to set funding levels for health and human services that include medical research during the fiscal year ahead, 679 clinicians and researchers as well as leaders of 416 organizations working to prevent, treat and some day end the impact of HIV, have added their names to […]

START findings highlight treatment divide

By on .

“It’s just more scientific evidence to back what we’ve been saying for a long time.” Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, announcing the conclusion of the START trial, which began in 2011 to assess “the best time for healthy HIV-infected people to begin antiretrovirals.” The announcement from the National Institute […]

START Trial data support starting antiretroviral treatment for HIV as early as possible

By on .

An international trial has shown that starting antiretroviral treatment for HIV early significantly lowers risks of serious illnesses, including AIDS, compared to waiting for immune cell counts to drop. The START — Strategic Timing of AntiRetroviral Treatment clinical trial — which enrolled 4,685 people living with HIV at 215 sites across 35 countries over the […]

Budget cuts threaten HIV vaccine development, say experts

By on .

New HIV infections would decrease by 40 percent within ten years after the launch of an HIV vaccine, experts said at an HIV Vaccine Awareness Day event on Monday hosted by AVAC, IAVI and the Bill and Melinda Gates Foundation. Advancements in technology have paved the way for an effective HIV vaccine, but progress is threatened […]

HPTN Annual Meeting: The story of Project Accept one of both process and results

By on .

The HIV Prevention Trials Network is holding its annual meeting in Washington, DC this week, and Science Speaks is there, covering Monday, Tuesday and Wednesday sessions. As Tom Coates was getting ready to discuss the results of Project Accept, a 10-year study of the impact of community involvement HIV efforts on community-wide HIV incidence, he […]

HIV prevention: on the verge of transformation

By on .

A look at the recent AIDS Vaccine 2012 Conference shows range of prevention developments The following is a guest post from Margaret McGlynn, president and CEO of the International AIDS Vaccine Initiative (IAVI) and William Snow, director of the Global HIV Vaccine Enterprise. More than 1,000 HIV researchers and other professionals involved in HIV prevention […]

Thai trial yield continues with news vaccine changed virus

By on .

The vaccine that showed a vaccine can prevent HIV infection also has shown that the vaccine changed the virus in people who did become infected, according to research revealed today in the first plenary session of AIDS Vaccine 2012. The findings were the third revelation from a study that first generated excitement in the AIDS […]

AIDS Vaccine 2012: Of YECIs and generations of work

By on .

BOSTON, MA — When Bill Snow, now director of the Global HIV Vaccine Enterprise, first became interested in the quest for a vaccine against the AIDS virus, he had a life expectancy of less than 10 years, he said Sunday. That was in 1989, he told the audience gathered for the opening of AIDS Vaccine […]